• Thumbnail for Daratumumab
    Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed...
    22 KB (1,823 words) - 07:01, 8 August 2024
  • Daratumumab/hyaluronidase, sold under the brand name Darzalex Faspro, is a fixed-dose combination medication for the treatment of adults with newly diagnosed...
    11 KB (954 words) - 06:56, 8 August 2024
  • cyclophosphamide, bortezomib and dexamethasone (CyBorD) with daratumumab added. Daratumumab, a monoclonal antibody to CD38, a protein that is expressed...
    16 KB (1,638 words) - 03:32, 26 August 2024
  • Thumbnail for CD38
    marker in leukemia. Daratumumab (Darzalex) which targets CD38 has been used in treating multiple myeloma. The use of Daratumumab can interfere with pre-blood...
    35 KB (3,825 words) - 06:11, 5 June 2024
  • Thumbnail for Antibody-dependent cellular cytotoxicity
    vitro during trastuzumab treatment. Multiple myeloma can be treated with daratumumab (Darzalex) monoclonal antibody. Studies with in vitro materials and patient...
    13 KB (1,661 words) - 22:18, 9 December 2023
  • cancer (Seagen) Marketed by partners: Darzalex (IV) (daratumumab) / Darzalex Faspro (SC) (daratumumab and hyaluronidase) for the treatment of all stages...
    26 KB (1,906 words) - 04:10, 19 June 2024
  • Thumbnail for Hyaluronidase
    (Rituxan Hycela), trastuzumab/hyaluronidase-oysk (Herceptin Hylecta), daratumumab/hyaluronidase-fihj (Darzalex Faspro), and pertuzumab/trastuzumab/hyaluronidase–zzxf...
    31 KB (2,902 words) - 11:13, 6 August 2024
  • symptoms of the TEMPI syndrome was reported with the drugs bortezomib, daratumumab and autologous stem cell transplantation. In 2010, the case of a man...
    5 KB (366 words) - 01:35, 11 April 2024
  • Thumbnail for Multiple myeloma
    groupings include one or more of a monoclonal antibody (e.g., isatuximab or daratumumab), an immunomodulatory agent (e.g., lenalidomide or pomalidomide), and...
    131 KB (13,479 words) - 19:40, 29 August 2024
  • 1007/978-3-540-47648-1_1505. ISBN 978-3-540-36847-2. "Summary of opinion: Darzalex,daratumumab". Case Medical Research. 2019-12-13. doi:10.31525/cmr-242ed13. ISSN 2643-4652...
    25 KB (1,860 words) - 04:49, 26 July 2024